O.K!! here's a copy of your post with Menon's name highlighted!!
-------------------------------------------------------------
Cryptophycin compound
Abstract
The present invention provides antitumor methods, formulations, and compounds comprising a cryptophycin.
--------------------------------------------------------------------------------
Inventors: Corbett; Thomas Hughes (Grosse Pointe Park, MI), Moore; Richard Elliott (Honolulu, HI), Liang; Jian (Honolulu, HI)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Wayne State University (Detroit, MI)
University of Hawaii (Honolulu, HI)
Appl. No.: 09/915,638
Filed: July 26, 2001
--------------------------------------------------------------------------------
Current U.S. Class: 514/183 ; 540/451
Current International Class: C07D 273/00 (20060101)
Field of Search: 514/183 540/451
--------------------------------------------------------------------------------
References Cited [Referenced By]
--------------------------------------------------------------------------------
U.S. Patent Documents
6013626 January 2000 Moore et al.
6180679 January 2001 Shih et al.
Foreign Patent Documents
WO 98/08505 Mar., 1998 WO
Other References
Chen B. et al, Cellular Uptake of a Novel Cytotoxic Agent, Cryptophycin-52, By Human THP-1 Leukemia Cells and H-125 Lung Tumor Cells, Int. J. Cancer (1998), 77, pp869-873. .
Panda D. et al, Mechanism of Action of the Unusually Potent Microtubule Inhibitor Cryptophycin 1, Biochemisty (1997), 36, pp12948-12953. .
Smith C. et al, Cryptophycin: A New Antimicrotubule Agent Active Against Drug-Resistant Cells, Cancer Research (Jul. 15, 1994), 54, pp3779-3784. .
Wagner M. et al, In Vitro Pharmacology of Cryptophycin 52 (LY355703) in Human Tumor Cell Lines, Cancer Chemother. Pharmacol. (1999), 43, pp115-125. .
Panda D. et al., Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends, Proc. Natl. Acad. Sci. (Aug. 1998), 95:9313-9318. .
Teicher B. et al., Cryptophycin 52 and Cryptophycin 55 in Sequential and Simultaneous Combination Treatment Regimens in Human Tumor Xenografts, In Vivo (2000), 14:471-480. .
Moore R. et al., The Search for New Antitumor Drugs from Blue-Green Algae, Current Pharmaceutical Design (1996), 2:317-330. .
Liang J. et al., Synthesis of Cryptophycin 52 Using the Sharpless Asymmetric Dihydroxylation: Diol to Epoxide Transformation Optimized for a Base-Sensitive Substrate, J. Org. Chem. (2000), 65:3143-3147. .
Gardinier K. et al., Enantiospecific Total Synthesis of the Potent Antitumor Macrolides Cryptophycins 1 and 8, J. Org. Chem (1997), 62(21):7098-7099. .
Norman B. et al., Total Synthesis of Cryptophycin Analogues. Isosteric Replacement of the C-D Ester, J. Org. Chem. (1998), 63(15):5288-5294. .
Golakoti T. et al., Structure Determination, Conformational Analysis, Chemical Stability Studies, and Antitumor Evaluation of the Cryptophycins. Isolation of 18 New Analogs from Nostoc sp. Strain GSV 224, J. Am. Chem. Soc. (1995), 117:12030-12049. .
Menon K. et al., Antitumor activity of cryptophycins: effect of infusion time and combination studies, Cancer Chemother. Pharmacol. (2000), 46:142-149. .
Georg G. et al., Halohydrin Analogues of Cryptophycin 1: Synthesis and Biological Activity, Bioorganic & Medicinal Chemistry Letters 8 (1998), pp1959-1962..
Primary Examiner: Kifle; Bruck
Attorney, Agent or Firm: Merchant & Gould P.C.
AI
